These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34207028)

  • 1. Novel Therapeutic Advances in β-Thalassemia.
    Makis A; Voskaridou E; Papassotiriou I; Hatzimichael E
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34207028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2017 Clinical trials update in new treatments of β-thalassemia.
    Makis A; Hatzimichael E; Papassotiriou I; Voskaridou E
    Am J Hematol; 2016 Nov; 91(11):1135-1145. PubMed ID: 27502996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
    Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
    Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
    Langer AL; Esrick EB
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent trends in treatment of thalassemia.
    El-Beshlawy A; El-Ghamrawy M
    Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
    Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
    Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyruvate kinase activators: targeting red cell metabolism in thalassemia.
    Kuo KHM
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):114-120. PubMed ID: 38066911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ineffective erythropoiesis and its treatment.
    Cazzola M
    Blood; 2022 Apr; 139(16):2460-2470. PubMed ID: 34932791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights Into Pathophysiology of β-Thalassemia.
    Sanchez-Villalobos M; Blanquer M; Moraleda JM; Salido EJ; Perez-Oliva AB
    Front Med (Lausanne); 2022; 9():880752. PubMed ID: 35492364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
    Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
    Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
    Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Ineffective Erythropoiesis in Thalassemia: A Hope on the Horizon.
    Madan U; Bhasin H; Dewan P; Madan J
    Cureus; 2021 Oct; 13(10):e18502. PubMed ID: 34754662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Αlpha-thalassemia: A practical overview.
    Musallam KM; Cappellini MD; Coates TD; Kuo KHM; Al-Samkari H; Sheth S; Viprakasit V; Taher AT
    Blood Rev; 2024 Mar; 64():101165. PubMed ID: 38182489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia.
    Gabbianelli M; Morsilli O; Massa A; Pasquini L; Cianciulli P; Testa U; Peschle C
    Blood; 2008 Jan; 111(1):421-9. PubMed ID: 17951528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.
    Longo F; Piolatto A; Ferrero GB; Piga A
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells.
    Rattananon P; Anurathapan U; Bhukhai K; Hongeng S
    Front Pharmacol; 2021; 12():730873. PubMed ID: 34658870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Therapies in β-Thalassemia.
    Bou-Fakhredin R; Kuo KHM; Taher AT
    Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.